Last quarter (Q4 2022), Nanobiotix's total revenue was €―, a decrease of ― from the same quarter last year. In Q4, Nanobiotix's net income was €―. See Nanobiotix’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	€ 4.78M	€ 2.65M	€ 50.00K	€ 68.00K	€ 116.00K
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	€ 4.78M	€ 10.00K	-	-	-
Operating Expense	-	€ 64.36M	€ 49.81M	€ 36.48M	€ 46.85M	€ 30.18M
Operating Income	-	€ -64.36M	€ -49.80M	€ -36.43M	€ -46.78M	€ -30.07M
Net Non Operating Interest Income Expense	-	€ 3.53M	€ 6.36M	€ 4.44M	€ -4.55M	€ -726.00K
Other Income Expense	-	€ -3.79M	€ 2.78M	€ -1.59M	€ 423.00K	-
Pretax Income	-	€ -57.03M	€ -47.00M	€ -33.58M	€ -50.91M	€ -30.34M
Tax Provision	-	€ 10.00K	€ 5.00K	€ 9.00K	€ 3.00K	€ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	€ -57.04M	€ -47.00M	€ -33.59M	€ -50.91M	€ -30.34M
Basic EPS	-	€ -1.64	€ -1.35	-	-	-
Diluted EPS	-	€ -1.64	€ -1.35	-	-	-
Basic Average Shares	-	€ 34.85B	€ 34.73B	-	-	-
Diluted Average Shares	-	€ 34.78M	€ 34.82M	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	€ 6.48M	€ 9.44M	€ 5.92M
Total Expenses	-	€ 64.36M	€ 49.81M	€ 36.48M	€ 46.85M	€ 30.18M
Net Income From Continuing And Discontinued Operation	-	€ -57.04M	€ -47.00M	€ -33.59M	€ -50.91M	€ -30.34M
Normalized Income	-	-	-	€ -32.00M	€ -51.34M	€ -30.34M
Interest Expense	-	-	-	€ 333.00K	€ 4.79M	€ 847.00K
EBIT	-	€ -51.43M	€ -46.62M	€ -33.25M	€ -46.12M	€ -29.50M
EBITDA	-	€ -49.93M	€ -45.06M	€ -31.49M	€ -44.35M	€ -28.88M

Currency in EUR

Nanobiotix Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing